Invent Medic Sweden (IMS) Investor update summary

Strategic priorities

• Proceeds from the share issue are intended to support three areas: expand Efemia Bladder Support distribution, build FlowCup partnerships with more NGOs, and grow the women’s health portfolio through acquisitions and collaborations.

• Efemia priorities include adding and supporting European distributors, training Swedish prescribers, exploring markets outside Europe, and making the product the first choice for women with stress urinary incontinence.

• UriCap Female is being established in Sweden through selected clinics and regions, with plans for consumer access via assistive device centers; acquisition discussions for MeCovers are to continue after the share issue.

• Management highlighted a fragmented women’s health market and expected sector consolidation as an opportunity; the business has products on the market, MDR approval, and an established organization.

Commercial progress

• Six new Efemia Bladder Support distributors signed in 2024, including partners in Denmark in May, Hungary in June, and New Zealand in September; New Zealand was the second distributor outside Europe.

• FlowCup received a significant order for 7,000 units in September, supporting efforts to build lasting partnerships with NGOs.

Portfolio expansion

• A September LOI with MeCovers covers products expected to complement the women’s health portfolio; MeCovers’ owner committed to invest SEK 600,000 toward financing operations.

• Management attributed Efemia’s growth to activities undertaken over recent years and expects greater returns as products, partnerships, and distributors are added.